Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MegaPro Biomedical CoROCO:6827 -2.28%32 FCF Yield % is -13.75 as of Jul. 18, 2026. GuruFocus rates ROCO:6827 with a GF Score™ of 32/100. Among 1,409 Biotechnology companies, MegaPro Biomedical Co ranks worse than 57.91% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
MegaPro Biomedical Co FCF Yield % Related Terms
MegaPro Biomedical Co FCF Yield % Historical Data
* Premium members only.
The historical data trend for MegaPro Biomedical Co's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6827 vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, MegaPro Biomedical Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MegaPro Biomedical Co FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MegaPro Biomedical Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where MegaPro Biomedical Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MegaPro Biomedical Co (ROCO:6827) has a FCF Yield % of -13.75 as of Jul. 18, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MegaPro Biomedical Co and its competitors. According to the industry distribution chart, MegaPro Biomedical Co ranks #816 out of 1409 companies in the Biotechnology industry, placing it in the top 57.9%.
Is MegaPro Biomedical Co's FCF Yield % too high?
MegaPro Biomedical Co's current FCF Yield % is -13.75. Based on the distribution chart, MegaPro Biomedical Co ranks #816 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MegaPro Biomedical Co has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does MegaPro Biomedical Co's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MegaPro Biomedical Co ranks #816 out of 1409 companies for FCF Yield %. This places MegaPro Biomedical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MegaPro Biomedical Co and its competitors. MegaPro Biomedical Co's current FCF Yield % is -13.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MegaPro Biomedical Co stock overvalued right now?
MegaPro Biomedical Co (ROCO:6827) has a current FCF Yield % of -13.75. The current FCF Yield % is -13.75. MegaPro Biomedical Co's overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For MegaPro Biomedical Co (ROCO:6827), the current FCF Yield % is -13.75 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MegaPro Biomedical Co Ltd is a nanomedicine development company. The Company's only reportable operating segment is the Drug Application Development segment, which is engaged in the development of nano-iron oxide IOP drugs.
32GF Score
Get the complete analysis for ROCO:6827
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6827 has been successfully added to your 
